IRONWOOD PHARMACEUTICALS INC - Class A Common Stock (IRWD)

CUSIP: 46333X108

Q4 2025 13F Holders as of 31 Dec 2025

Holder snapshot 7 signals
Share change
+6,460,869
Put/Call ratio
0.24%
SEC-reported price per share
$3.37
Number of holders
196
Value change
+$36,443,345
Number of buys
115
Open additional details 1 more signal available
Number of sells
63
Security identity Names, identifiers, and filing context for this profile. 1 source field
Shares outstanding
163,103,594

Security key

46333X108

Report period

Q4 2025

Institutions

196

Top holders

10

Ownership snapshot

Top reported holders of IRWD - IRONWOOD PHARMACEUTICALS INC - Class A Common Stock (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
VANGUARD GROUP INC
Disclosed value leader
ARMISTICE CAPITAL, LLC
Comparable rows
4/15
Latest evidence
30 Sep 2025
13F 13D/G 3/4/5 Lead comparable stake: 10% 11 rows are not safely comparable across share classes. 13D/G row: VANGUARD GROUP INC Showing 1-6 of 15 holder rows.

Quick read

VANGUARD GROUP INC leads the comparable SEC ownership view at 10%.

4 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens VANGUARD GROUP INC's linked filing trail.
Comparable ownership Top 4
VANGUARD GROUP INC 10%
RENAISSANCE TECHNOLOGIES LLC 5.4%
BARCLAYS PLC 2%
Pacer Advisors, Inc. 1.1%

Ownership % is shown only when SEC disclosures are safely comparable across share classes.

Detailed SEC evidence table Showing 1-6 of 15 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
VANGUARD GROUP INC
13F 13D/G
Company · The Vanguard Group
10%
Reported 13D/G · 30 Jun 2025
$21,054,327
16,072,006 shares
— 30 Sep 2025
RENAISSANCE TECHNOLOGIES LLC
13F 13D/G
Company
5.4%
Reported 13D/G · 15 May 2024
$10,941,347
8,352,173 shares
— 30 Sep 2025
BARCLAYS PLC
13D/G 13F
Company
2%
Reported 13D/G · 30 Sep 2025
$4,149,704
3,167,713 shares
-$10,435,649 30 Sep 2025
Pacer Advisors, Inc.
13D/G
Pacer US Small Cap Cash Cows ETF
1.1%
Reported 13D/G · 31 Mar 2025
$1,574,406
1,789,098 shares
-$8,748,672 31 Mar 2025
ARMISTICE CAPITAL, LLC
13F
Company
13F
—
denominator unverified
$21,156,500
16,150,000 shares
— 30 Sep 2025
Sarissa Capital Management LP
13F
Company
13F
—
denominator unverified
$20,854,460
15,919,435 shares
— 30 Sep 2025
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q4 2025

Investor-level positions for this CUSIP, loaded as an interactive table.

Institutions
196
Shares
153,978,212
Rows available
196
Investor Option Weight % Change % SEC-reported value * Price Shares Share Change Activity Report Period

* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Compare Q4 2025 vs Q3 2025 Across Filers

Q3 2025 holders
160
Q4 2025 holders
196
Holder diff
36
Investor Q3 2025 Shares Q4 2025 Shares Share Diff Share Chg % Q3 2025 value Q4 2025 value Value change Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .